Pomalidomide, >=98% (HPLC)

Pomalidomide, >=98% (HPLC)

Application

Pomalidomide has been used:to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptidesfor apoptosis studies and intracellular calcium analysisas a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β;-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells

Biochem/physiol Actions

Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.

Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key γ-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573513 Pomalidomide, >=98% (HPLC) yellow 100 UVSMNLNDYGZFPF-UHFFFAOYSA-N 1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) SIGMA-ALDRICH powder ≥98% (HPLC)
£671.36 (exc VAT) per 25MG
-
+
3573514 Pomalidomide, >=98% (HPLC) yellow 100 UVSMNLNDYGZFPF-UHFFFAOYSA-N 1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) SIGMA-ALDRICH powder ≥98% (HPLC)
£190.82 (exc VAT) per 5MG
-
+